WHO maintains public health emergency alert on mpox
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2025
0mins
Source: SeekingAlpha
WHO's Classification of Mpox: The World Health Organization continues to classify mpox as a public health emergency of international concern, with a new variant, clade Ib, primarily affecting the Democratic Republic of Congo, Uganda, and Burundi, while also appearing in travel-related cases globally.
Vaccination and Diagnostic Measures: WHO has updated its guidance to include targeted vaccination in outbreak areas and increased access to diagnostic testing to help control the spread of mpox, with several companies involved in developing vaccines and tests for the disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EBS is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.900
Low
15.00
Averages
15.00
High
15.00
Current: 11.900
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement
- Insider Trading Lawsuit: New York Attorney General Letitia James has sued former CEO Robert G. Kramer for allegedly using nonpublic information to trade Emergent stock in 2020, undermining public trust.
- Settlement Agreement: Emergent has agreed to pay $900,000 in penalties and strengthen executive stock trading controls and policies, demonstrating the company's commitment to compliance and ethical governance.
- Vaccine Production Issues: The lawsuit highlights contamination problems discovered by Emergent in September and October 2020, leading to an FDA order to halt AstraZeneca production in April 2021, which adversely affected the company's production capacity and market reputation.
- Trading Plan Controversy: Kramer’s trading plan, approved in November 2020, allowed him to sell shares in January and February 2021, netting over $10.1 million, illustrating the legal risks associated with executive trading under insider information.
Continue Reading
Emergent Biosolutions' Former CEO Sued for Insider Trading, Facing $900,000 Penalty
- Insider Trading Allegations: New York Attorney General Letitia James has sued Emergent's former CEO Robert Kramer for insider trading, alleging he executed a trading plan while aware of manufacturing and contamination issues, leading to a 13% drop in the company's stock price.
- Contract Background: Emergent inked a $261 million contract with AstraZeneca in 2020 to produce COVID-19 vaccines, but large quantities were rendered unusable due to contamination, adversely affecting the company's reputation and financial health.
- Fines and Settlement: Emergent agreed to pay $900,000 in penalties as part of a settlement with the Attorney General, while committing to improve executive trading policies to prevent future violations, demonstrating the company's focus on compliance.
- Market Reaction: Despite facing legal challenges, Emergent's stock has gained 15% over the past 12 months, and investor sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', indicating market confidence in the company's future prospects.
Continue Reading